<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The c-mpl proto-oncogene which encodes a member of the hematopoietic cytokine receptor superfamily has been recently shown to be the receptor for thrombopoietin (TPO), which stimulates megakaryocyte progenitor expansion and differentiation </plain></SENT>
<SENT sid="1" pm="."><plain>We studied c-mpl expression by Northern blot analysis, in a large series of 58 MDS </plain></SENT>
<SENT sid="2" pm="."><plain>No expression was found in 14 patients with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (RA) or with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with ring sideroblasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>In contrast 11/26 (42%) patients with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess of blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>), or with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in transformation (RAEBt), and 8/18 (44%) patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) expressed c-mpl </plain></SENT>
<SENT sid="4" pm="."><plain>In <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> patients, no correlation was found between c-mpl expression and any prognostic factor tested, nor with the course of the disease </plain></SENT>
<SENT sid="5" pm="."><plain>In contrast, in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> and RAEBt, expression of c-mpl was correlated with high Bournemouth scoring (P &lt; 0.005) and poor survival (P = 0.02) due to leukemic transformation </plain></SENT>
<SENT sid="6" pm="."><plain>Forty-five per cent (5/11) of the c-mpl positive patients evolved towards <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with a mean follow-up of 10.5 months, while 13% (2/15) of the c-mpl negative patients developed a secondary <z:hpo ids='HP_0001909'>leukemia</z:hpo>, with a mean follow-up of 21.1 months </plain></SENT>
<SENT sid="7" pm="."><plain>Moreover, in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> and RAEBt, a significant correlation was observed between c-mpl, CD34, megakaryocyte <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> IIb (GPIIb) expression, and the presence of dysmegakaryopoiesis </plain></SENT>
<SENT sid="8" pm="."><plain>These results indicate that patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> and RAEBt, with high expression of the c-mpl, CD34, and GPIIb genes, may identify a subgroup of patients with particularly poor prognosis, due to an increased risk of secondary <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>More aggressive therapy could be justified in these patients </plain></SENT>
</text></document>